GlassScriptPhysician profile
Brett Steinwand
NPI 1932199916
$892.25
in general payments reported to CMS, 2019-2025
19 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.29 · 2021: $66.36 · 2022: $123 · 2023: $128 · 2024: $337 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $620 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $620.08 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $123.59 | 2023-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $107.73 | 2021-2024 | Eylea, Eylea Hd |
| Bausch & Lomb Americas INC. | $69.95 | 2024-2025 | Miebo, Xiidra, Stellaris |
| Harrow Eye, LLC | $69.14 | 2024-2025 | Triesence, Iheezo |
| Alcon Vision LLC | $66.16 | 2024 | Centurion |
| Allergan, INC. | $59.78 | 2019-2022 | |
| Dompe US, INC. | $56.72 | 2024-2025 | Oxervate |
| Genentech USA, INC. | $55.35 | 2022-2024 | Vabysmo |
| Rayner Intraocular Lenses Limited | $37.08 | 2024 | Omidria, Rayone Aspheric, Rayone Emv |
| Sight Sciences, INC. | $35.19 | 2019-2021 | |
| Amgen INC. | $33.67 | 2025 | Tepezza |
| Ocular Therapeutix, INC. | $33.43 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $32.69 | 2024 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $29.01 | 2023 | Tecnis Iol |
| New World Medical,INC. | $20.90 | 2023-2024 | Clearpath, Streamline, Kahook Dual Blade |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $17.10 | 2025 | Tyrvaya, Ryzumvi |
| Horizon Therapeutics Plc | $15.82 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.22 | 2019 | |
| Eyepoint US, INC. | $13.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Steinwand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.